Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578808 | 0.90 | MAPT (0.57) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL2216223 | 0.88 | MEN1 (0.54) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578827 | 0.88 | SMN1; SMN2 (0.56) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578846 | 0.87 | L3MBTL1 (0.62) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL2219207 | 0.86 | GAA (0.57) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578835 | 0.86 | MEN1 (0.64) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL2218076 | 0.85 | MEN1 (0.73) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578577 | 0.84 | MEN1 (0.52) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578103 | 0.83 | MEN1 (0.58) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL1578022 | 0.83 | MAPT (0.53) | LMNAMEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| CN-103983627-A | Pyridopyrimidine compounds as anti-tubercular agents | PASTEUR INSTITUT KOREA | 2014-08-13 | — | — | CN | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| CN-102105470-B | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2014-06-04 | — | — | CN | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| CN-102105470-A | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2011-06-22 | — | — | CN | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | LMNA 4132/4885MEN1 3685/4885KMT2A 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.